The Patent Finder

Neovacs

Also on record
Records under this name other than the patents Neovacs holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.

Back to Neovacs

PatentTitleStatus Expires Confidence
US 9,993,565Method for treating IFNalpha related conditions
Lapsed on the fee record
Ended Jun 12, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jun 12, 2026From the USPTO record
US 8,372,388Method for preparing a stable TNF-α vaccine
Term ended
Term ended Dec 6, 2024 · From the USPTO record
Term endedTerm ended Dec 6, 2024From the USPTO record
US 7,972,603Stable immunogenic product comprising antigenic heterocomplexes
Term ended
Term ended Sep 16, 2023 · From the USPTO record
Term endedTerm ended Sep 16, 2023From the USPTO record
US 8,697,047Stable immunogenic product comprising antigenic heterocomplexes
Term ended
Term ended Sep 16, 2023 · From the USPTO record
Term endedTerm ended Sep 16, 2023From the USPTO record
US 7,015,016Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's
Term ended
Term ended Feb 9, 2022 · From the USPTO record
Term endedTerm ended Feb 9, 2022From the USPTO record
US 6,420,141Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids
Formerly held
Term ended
Term ended Mar 15, 2021 · From the USPTO record
Term endedTerm ended Mar 15, 2021From the USPTO record
US 6,200,575Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
Term ended
Term ended May 15, 2020 · From the USPTO record
Term endedTerm ended May 15, 2020From the USPTO record
US 6,878,370Chemically modified TNF-α
Term ended
Term ended Apr 20, 2020 · From the USPTO record
Term endedTerm ended Apr 20, 2020From the USPTO record
US 7,351,554Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's
Lapsed on the fee record
Ended Apr 1, 2020 · From the USPTO record
Lapsed on the fee recordEnded Apr 1, 2020From the USPTO record
US 8,101,165Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors
Lapsed on the fee record
Ended Jan 24, 2020 · From the USPTO record
Lapsed on the fee recordEnded Jan 24, 2020From the USPTO record
10 of 20 patents shown.
Pro members see all 20.
Pro members: see all 20 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited